Domestic drug companies to activate development of bio-engineering products

Published: 2002-01-21 07:00:00

Updated: 2002-01-21 07:00:00

To pave an advanced way for the forthcoming bio-tech era the domestic leading pharmaceutical companies are actively taking part in the R&D investment for the development of bio-engineering products in view of keeping the future competitiveness over the world.

Dong-A who earlier opened wide eyes on this research area succeeded in commercializing 4 bio-tech products like Eporon, a new erythro...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.